Elamiretide (SS-31) —
Protecting the Inner Mitochondrial Membrane

Aromatic-cationic tetrapeptide — D-Arg-2'6'-dimethylTyr-Lys-Phe-NH₂

SS-31, Bendavia, MTP-131

Inner mitochondrial membrane — selectively concentrates 1000x+ vs. cytoplasm via electrostatic attraction

Cardiolipin binding → ETC supercomplex stabilization, mitochondrial ROS scavenging, IMM structural preservation

Studied in heart failure, renal ischemia-reperfusion, age-related mitochondrial dysfunction (Phase 1/2 as Bendavia/MTP-131)

Subcutaneous injection — 15mg/mL, 5mL vial

Selective IMM Concentration via Electrostatic Targeting

The inner mitochondrial membrane maintains one of the most strongly negative electrochemical potentials in biology — the proton gradient that drives ATP synthesis. Elamiretide carries a net positive charge, and this electrostatic mismatch drives its spontaneous concentration across two membranes to accumulate in the inner membrane at concentrations estimated to be 1,000–5,000 times higher than in the surrounding cytoplasm. This concentration gradient is self-sustaining as long as the mitochondrial membrane potential is intact. Elamiretide does not require a transporter — it physically migrates to its site of action. This targeting specificity is what distinguishes it from general antioxidants, which distribute broadly throughout the cell.

Cardiolipin Binding and ETC Supercomplex Stabilization

Cardiolipin is a dimeric phospholipid found almost exclusively in the inner mitochondrial membrane, where it serves a structural function unlike any other membrane lipid. It acts as a molecular scaffold that organizes the electron transport chain complexes — particularly Complex I, Complex III, and cytochrome c — into functional supercomplexes called respirasomes. These supercomplexes are necessary for efficient electron channeling between ETC components, and their integrity determines how efficiently the mitochondria can convert substrate into ATP. Oxidative stress damages cardiolipin through lipid peroxidation, causing ETC complexes to dissociate and reducing efficiency. Elamiretide binds cardiolipin, protects it from peroxidation, and stabilizes the supercomplex architecture.

Mitochondria-Localized ROS Scavenging

Reactive oxygen species (ROS) are a byproduct of normal mitochondrial electron transport — electrons that escape the ETC before reaching Complex IV react with oxygen to generate superoxide and hydrogen peroxide. Mitochondria have intrinsic ROS defense systems, but these can be overwhelmed under conditions of metabolic stress, disease, aging, or high oxidative demand. Because Elamiretide concentrates specifically in the IMM — precisely where mitochondrial ROS are generated — it scavenges ROS at their source before they propagate into the broader cellular environment and before they can damage cardiolipin or ETC components.

Cytochrome c Retention and Apoptosis Regulation

Cytochrome c is a small electron carrier protein that shuttles electrons between Complex III and Complex IV — it is an essential ETC component. It is also, when released from the mitochondria into the cytoplasm, a trigger for apoptosis (programmed cell death). Under conditions of severe oxidative stress, cardiolipin oxidation releases cytochrome c from its IMM binding site, initiating apoptotic signaling. Elamiretide's cardiolipin stabilization retains cytochrome c in its functional position in the ETC, preserving both electron transport efficiency and preventing apoptotic cascade initiation.

The Structural Niche in a Mitochondrial Stack

NAD+ replenishes the cofactor the ETC needs to operate. MOTS-C drives the biogenesis of new mitochondria. SLU-PP-332 activates the gene expression programs that govern mitochondrial adaptation. Elamiretide protects the structural integrity of the membrane all of that activity depends on. These mechanisms do not overlap — they address different levels of mitochondrial biology, and patients building comprehensive mitochondrial optimization stacks use them together for this reason.

Patients Building Comprehensive Mitochondrial Stacks

Patients already using NAD+, MOTS-C, or SLU-PP-332 who want to add the structural protection layer those compounds do not provide. Each increases mitochondrial activity — Elamiretide protects the membrane infrastructure that increased activity stresses. It is the most natural completion of a comprehensive mitochondrial protocol.

Longevity-Focused Patients Targeting Mitochondrial Aging

Mitochondrial dysfunction is one of the hallmarks of aging — and cardiolipin oxidation and ETC supercomplex disorganization are among the earliest mitochondrial aging events. Elamiretide addresses this specifically at the structural level.

Patients with High Oxidative Stress Exposure

Athletes in high-volume or high-intensity training, patients with chronic inflammatory conditions, patients post-illness or post-surgery — anyone with elevated mitochondrial ROS burden benefits from Elamiretide's localized scavenging.

Patients with Cardiovascular or Renal Risk

The heart and kidneys are the highest-energy-demand, most mitochondria-dependent organs. Patients with cardiovascular risk factors, a history of cardiac events, or chronic kidney disease may find Elamiretide relevant. Provider evaluation is essential.

Patients Experiencing Fatigue or Energy Decline

When fatigue is rooted in mitochondrial inefficiency rather than low mitochondrial quantity or NAD+ depletion, addressing ETC structural integrity may be the most direct intervention. Worth considering for patients who have tried NAD+ without the expected energy response — their barrier may be ETC structural disorganization.

Available Concentration

Elamiretide is available as a 15mg/mL, 5mL injectable vial (75mg total). Subcutaneous administration.

Typical Dose Range

Research and clinical protocols have used a range from 0.05mg/kg to 0.5mg/kg depending on indication and intensity. Longevity and optimization protocols typically use lower doses than acute clinical applications. Your provider will establish the appropriate dose for your protocol and body weight.

Frequency and Timing

Commonly dosed 3–5 times per week in optimization protocols. Timing relative to training or periods of high oxidative demand can be discussed with your provider — some patients prefer pre-training administration to protect the IMM during elevated mitochondrial ROS production.

Cycle Structure

Well-tolerated for continuous use in clinical and research contexts. Optimization protocols are commonly run in 8–12 week cycles. Its protective function means it is most relevant when other mitochondrial activators are also in use.

Stacking Considerations

The three most natural stack partners: NAD+ (ETC cofactors that Elamiretide's structural preservation makes more efficient), MOTS-C (mitochondrial biogenesis — Elamiretide protects new mitochondria), and SLU-PP-332 (increases oxidative demand — Elamiretide provides structural protection). Together these four compounds address cofactors, biogenesis signaling, transcription factor activation, and membrane structural integrity.

Elamiretide (SS-31) 15mg/mL — 5mL Injectable

Elamiretide (SS-31) 15mg/mL, 5mL vial (75mg total). Subcutaneous injection. Selectively concentrates in the inner mitochondrial membrane via electrostatic targeting. Cardiolipin binding, ETC supercomplex stabilization, mitochondrial ROS scavenging. Syringes and alcohol swabs included.

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping
• Syringes and alcohol swabs